Anti-Glutamic Acid Decarboxylase 65 (5-22) antibody produced in rabbit

Description

• General description: GAD is predominantly expressed in the central nervous system (CNS) and pancreatic islets. It is also expressed in testis, oviduct and ovary. GAD exists in two isofoms, GAD 65 and GAD 67. GAD65 is targeted to membranes and nerve endings.
• Specificity: Reacts specifically with GAD 65 (65 kDa).
• Immunogen: synthetic peptide corresponding to the N-terminal region of human GAD 65 (amino acids 5-22). The sequence is highly conserved in rat and pig GAD 65 (single amino acid substitution) and mouse and monkey GAD 65, but is not found in GAD 67.
• Application: Anti-Glutamic Acid Decarboxylase 65 (5-22) antibody produced in rabbit has been used in immunohistochemistry and immunocytochemistry.
• Biochem/physiol Actions: Glutamic Acid Decarboxylase (GAD) catalyzes the conversion of L-glutamate to γ-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain, and a putative paracrine signal molecule in pancreatic islets. GAD65 is an ampiphilic, membrane-anchored protein, (585 amino acid residues) and is encoded on human chromosome 10. It has been identified as an autoantigen in insulin-dependent diabetes mellitus (IDDM) and stiff-man syndrome (SMS) and may serve as a marker in the early stages of IDDM. GAD 65 synthesizes transmitter GABA for vesicular release.
• Physical form: Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.